Nkarta, Inc. - 8-K Filing
Nkarta announces initial clinical data for NKX019 in myositis and systemic sclerosis trials with no reported cytokine release syndrome or neurotoxicity. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Financial Statements and Exhibits)